There are 101 papers on time in range in aging research: 28 trials and 56 observational studies in people, 12 reviews.
101 papers study it83 more mention it58 findings
23 new papers in 30 daysSee all 184 papers on time in range
At a glance
Higher time in range is associated with less sarcopenia and mild cognitive impairment in older people with type 2 diabetes. Physical-function links differ across observational studies, including a study with no clear link in older patients with type 2 diabetes. Trials report increases with caloric restriction and, in poorly controlled type 1 diabetes, hybrid closed-loop systems.
58 findings in 46 papers from 2021 to 2026, 17 of them since April 2026
“Domain-wise analysis shows that as TIR increased, the scores obtained for the Role Limitation due to Physical Health domain also increased significantly (p-value = 0.002), indicating that higher TIR correlated with fewer Role Limitations due to Physical Health.”
- Human trial28
- Humans56
- In silico1
Interventions
20Tirzepatide
upin humans7
7 studies
Tirzepatide
upin humans7
Tirzepatide increases time in range in humans (from 53.2% (standard deviation [SD]: 18.2) to 78.9% (SD: 6.8) (p = 0.041)).
Human trialup to 2 weeksn = 4
Tirzepatide is linked with higher time in range in humans (+7.4% at 12 months).
Humansadjunctive use in overweight or obese adults with T1D, compared with computer-matched controls12 monthsn = 61
Tirzepatide is linked with higher time in range in humans (people with type 1 diabetes and obesity) (54.9% to 60.8%).
Humanspeople with type 1 diabetes and obesity3 monthsn = 36
Tirzepatide is linked with higher time in range in humans after switching from dulaglutide (42.7% to 50.8% (p = 0.02)).
Humansafter switching from dulaglutiden = 14
Tirzepatide is linked with higher time in range in humans (continuous glucose monitoring metrics).
Humanscontinuous glucose monitoring metricsn = 62
Tirzepatide is linked with higher time in range in humans (first tirzepatide administration, measured by continuous glucose monitoring) (53.2% to 78.9%).
Humansfirst tirzepatide administration, measured by continuous glucose monitoringmean measurement period 10.5 daysn = 4
Tirzepatide is linked with higher time in range in humans (adults with type 1 diabetes, uncontrolled comparison) (+12.6% (P = .002) for TIR; +10.7% (P = .0016) for TITR).
Humansadults with type 1 diabetes, uncontrolled comparison8 monthsn = 26
Tirzepatide is linked with higher time in range in a patient with type 1 diabetes and obesity (31% to 61% (doubled)).
Humansin a patient with type 1 diabetes and obesity2.5 mg weekly titrated to 7.5 mg weekly12 weeksfemalesn = 1
Semaglutide
downin humans1upin humans1upin silico1
3 studies
Semaglutide
downin humans1upin humans1upin silico1
Semaglutide decreases time in range in humans following treatment discontinuation (median change −3.6% vs. 1.5%).
Human trialfollowing treatment discontinuation3 monthsn = 38
Semaglutide is linked with higher time in range in humans (as an add-on therapy to insulin in LADA patients).
Humansas an add-on therapy to insulin in LADA patients6 monthsn = 68
Semaglutide increases time in range in silico (added to AIDANET fully closed-loop system, versus placebo) (73% to 87% versus placebo).
In silicoadded to AIDANET fully closed-loop system, versus placeboup to 1 mg/week
Caloric restriction
upin humans2
2 studies
Caloric restriction
upin humans2
Caloric restriction increases time in range in humans (92.4 ± 5% versus 81.4 ± 6.5%; p = 0.001).
Human trialType 2 diabetes of ≤5 years; compared with calorie-matched time-restricted intermittent fastingContinuous calorie-restricted dietDaily energy intake reduced by 500 kcal/dayn = 51
Caloric restriction improves time in range in humans (84.3% to 90.3%, P = 0.041).
Human trial12‐weekn = 24
Caloric restriction improves time in range in humans (84.3% to 90.3% (P = 0.041)).
Human trial12 weeks
Chenopodium quinoa
upin humans1
1 study
Chenopodium quinoa
upin humans1
Chenopodium quinoa increases time in range in humans.
Human trial14 weeksn = 60
Chenopodium quinoa increases time in range in humans (early-stage T2DM) (94.52 ± 4.88% vs 87.83 ± 9.9%, P <0.05).
Human trialearly-stage T2DMn = 60
Acarbose
no changein humans1
1 study
Acarbose
no changein humans1
Acarbose showed no clear effect on time in range in humans (add-on to metformin, compared with sitagliptin add-on).
Human trialadd-on to metformin, compared with sitagliptin add-on100 mg three times daily28 daysn = 701
Acarbose showed no clear effect on time in range in humans (89.15% (78.12%, 95.07%) vs. 88.72% (77.44%, 94.73%)).
Human trial28 daysn = 710
Combined aerobic and resistance training
upin humans1
1 study
Combined aerobic and resistance training
upin humans1
Combined aerobic and resistance training increases time in range in humans (type 2 diabetes mellitus; secondary comparison with aerobic training).
Human trialtype 2 diabetes mellitus; secondary comparison with aerobic trainingn = 23
Exercise mix linked to lower glucose in older type 2 diabetes patients
Journal of science and medicine in sport
Time-restricted feeding
upin humans1
1 study
Time-restricted feeding
upin humans1
Time-restricted feeding improves time in range in adults with T2DM on stable GLP-1RA, during sleep.
Human trialin adults with T2DM on stable GLP-1RA, during sleep8- to 10-hour eating window3 monthsn = 3
Open-source automated insulin delivery
upin humans1
1 study
Open-source automated insulin delivery
upin humans1
Open-source automated insulin delivery is linked with higher time in range in humans with adjunctive semaglutide, tirzepatide or SGLT-2 inhibitors (63% to 73% at 12 months).
Humanswith adjunctive semaglutide, tirzepatide or SGLT-2 inhibitors12 monthsn = 357
Insulin icodec + semaglutide
upin humans1
1 study
Insulin icodec + semaglutide
upin humans1
Insulin icodec + semaglutide is linked with higher time in range in humans (54.8% to 78.1%; 95% CI 9.5–25.5).
Humansdual therapy after switching from three or more glucose-lowering agents, compared with original therapyn = 66
Henagliflozin
upin humans1
1 study
Henagliflozin
upin humans1
Henagliflozin increases time in range in severely hyperglycaemic T2DM patients (79.85% vs. 74.06%, p = 0.005).
Human trialin severely hyperglycaemic T2DM patients7-dayn = 210
Morus alba
upin humans1
1 study
Morus alba
upin humans1
Morus alba increases time in range in humans.
Human trial14 daysn = 60
Intermittently scanned continuous glucose monitoring
upin humans1
1 study
Intermittently scanned continuous glucose monitoring
upin humans1
Intermittently scanned continuous glucose monitoring improves time in range in women with overweight or obesity participating in a structured lifestyle intervention (P = 0.03).
Human trialin women with overweight or obesity participating in a structured lifestyle intervention12-weekfemalesn = 35
More on Intermittently scanned continuous glucose monitoring
Hybrid closed-loop system
upin humans1
1 study
Hybrid closed-loop system
upin humans1
Hybrid closed-loop system increases time in range in humans (poorly controlled type 1 diabetes) (2-fold and 4-fold higher increase).
Human trialpoorly controlled type 1 diabetes12 months
COVID-19 vaccine
downin humans1
1 study
COVID-19 vaccine
downin humans1
COVID-19 vaccine decreases time in range in humans (type 1 diabetes mellitus) (45.2% vs 52.6%).
Human trialtype 1 diabetes mellitus7 daysn = 20
All 20Fewer
Effects
2Physical function
no changein humans1
1 study
Physical function
no changein humans1
Time in range was not clearly linked with physical function in older patients with type 2 diabetes mellitus.
Humansin older patients with type 2 diabetes mellitusn = 310
Sarcopenia
downin humans1
1 study
Sarcopenia
downin humans1
Time in range is linked with less sarcopenia in elderly patients with type 2 diabetes mellitus.
Humansin elderly patients with type 2 diabetes mellitusn = 280
Upstream
1Sarcopenia without adiposity
downin humans1
1 study
Sarcopenia without adiposity
downin humans1
Sarcopenia without adiposity is linked with lower time in range in humans (sarcopenia without adiposity in frail older adults with diabetes).
Humanssarcopenia without adiposity in frail older adults with diabetes
Associations
19Physical activity
upin humans2
2 studies
Physical activity
upin humans2
Physical activity is associated with time in range in humans (type 1 diabetes without confirmed cardiovascular autonomic neuropathy; adjusted analysis) (β = 15.22).
Humanstype 1 diabetes without confirmed cardiovascular autonomic neuropathy; adjusted analysisself-reportedhigh versus low physical activityn = 75
Physical activity is associated with time in range in humans (type 1 diabetes) (+8.0% TIR; -0.47% HbA1c).
Humanstype 1 diabeteshighest activity quartilen = 423
Mild cognitive impairment
downin humans2OR 0.917–0.92
2 studies
Mild cognitive impairment
downin humans2OR 0.917–0.92
Time in range is associated with mild cognitive impairment in humans (OR 0.92).
HumansPatients with type 2 diabetes mellitus and white matter hyperintensities; multivariable adjustmentn = 1,068
Time in range is linked with a lower risk of mild cognitive impairment in humans (older adult patients with type 2 diabetes mellitus) (OR 0.917, 95% CI 0.867-0.969, P = 0.002).
Humansolder adult patients with type 2 diabetes mellitusn = 203
Quality of life
upin humans1
1 study
Quality of life
upin humans1
Time in range is associated with quality of life in humans.
Human trialsix monthsn = 56
Time in range is associated with quality of life in humans (type 2 diabetes mellitus of less than 5 years' duration on Metformin only) (p = 0.002, p = 0.00).
Human trialtype 2 diabetes mellitus of less than 5 years' duration on Metformin only14-dayn = 51
Cardiovascular autonomic neuropathy
downin humans1
1 study
Cardiovascular autonomic neuropathy
downin humans1
Cardiovascular autonomic neuropathy is associated with time in range in humans (type 1 diabetes; confirmed CAN versus no confirmed CAN) (56.0% vs. 72.0%).
Humanstype 1 diabetes; confirmed CAN versus no confirmed CANn = 90
Ramadan fasting
upin humans1
1 study
Ramadan fasting
upin humans1
Ramadan fasting is associated with time in range in humans (60.8% to 65.0%; P < .001).
HumansType 2 diabetes receiving non-intensive diabetes therapy and using real-time continuous glucose monitoring; compared with pre-Ramadanduring Ramadann = 110
IL-6
downin humans1
1 study
IL-6
downin humans1
Time in range is associated with IL-6 in humans (exploratory CGM substudy in pregnant women with obesity) (-0.23 [95%CI: -0.43,-0.02]; p=0.035).
Humansexploratory CGM substudy in pregnant women with obesity24 weeks of gestationfemalesn = 18
Cardiovascular disease or all-cause death
downin humans1HR 0.73
1 study
Cardiovascular disease or all-cause death
downin humans1HR 0.73
Time in range is associated with cardiovascular disease or all-cause death in humans (Type 2 diabetes; adjusted model before mutual adjustment with HbA1c) (Adjusted HR 0.73 [0.61-0.87] per 20% TIR).
HumansType 2 diabetes; adjusted model before mutual adjustment with HbA1cMedian 2.3 yearsn = 1,363
Total cholesterol
downin humans1
1 study
Total cholesterol
downin humans1
Time in range is associated with total cholesterol in humans (type 2 diabetes mellitus; time in range >70%) (Total cholesterol decreased by 4.23 mg/dL in participants achieving TIR >70%).
Humanstype 2 diabetes mellitus; time in range >70%12 weeks
Handgrip strength
mixedin humans1
1 study
Handgrip strength
mixedin humans1
Time in range is associated with handgrip strength in older patients with type 2 diabetes mellitus.
Humansin older patients with type 2 diabetes mellitusn = 310
Skeletal muscle mass index
upin humans1
1 study
Skeletal muscle mass index
upin humans1
Time in range is associated with skeletal muscle mass index in older patients with type 2 diabetes mellitus.
Humansin older patients with type 2 diabetes mellitusn = 310
All 19Fewer
Funding
1 grant since 2019Health and Medical Research FundHK$1.4M
How this record changed
Summary written from the findings.